Jacob Chacko Sells 24,660 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 24,660 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $204,184.80. Following the sale, the chief executive officer now owns 778,648 shares in the company, valued at approximately $6,447,205.44. This trade represents a 3.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

ORIC Pharmaceuticals Price Performance

ORIC stock opened at $7.68 on Thursday. ORIC Pharmaceuticals, Inc. has a 1-year low of $6.33 and a 1-year high of $16.65. The stock has a market capitalization of $541.95 million, a P/E ratio of -4.27 and a beta of 1.13. The business has a fifty day moving average price of $9.33 and a 200-day moving average price of $9.36.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.01). As a group, analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. Wells Fargo & Company started coverage on ORIC Pharmaceuticals in a research note on Thursday, October 31st. They issued an “overweight” rating and a $20.00 target price on the stock. Stifel Nicolaus began coverage on ORIC Pharmaceuticals in a research report on Friday, September 6th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, ORIC Pharmaceuticals presently has an average rating of “Buy” and an average target price of $18.29.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORIC. Franklin Resources Inc. raised its stake in ORIC Pharmaceuticals by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock valued at $9,067,000 after buying an additional 196,804 shares during the last quarter. Barclays PLC grew its holdings in shares of ORIC Pharmaceuticals by 111.2% in the third quarter. Barclays PLC now owns 107,261 shares of the company’s stock worth $1,100,000 after acquiring an additional 56,474 shares during the period. Geode Capital Management LLC increased its position in ORIC Pharmaceuticals by 4.2% during the third quarter. Geode Capital Management LLC now owns 1,273,513 shares of the company’s stock valued at $13,056,000 after acquiring an additional 50,821 shares during the last quarter. M&T Bank Corp lifted its holdings in ORIC Pharmaceuticals by 19.2% in the third quarter. M&T Bank Corp now owns 85,137 shares of the company’s stock valued at $873,000 after acquiring an additional 13,711 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in ORIC Pharmaceuticals by 42.0% in the third quarter. Wellington Management Group LLP now owns 174,388 shares of the company’s stock valued at $1,787,000 after acquiring an additional 51,565 shares during the period. Hedge funds and other institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.